Citation Tools
PDFClinical/translational cancer immunotherapy
Original research
Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study